Professional Documents
Culture Documents
DEC. 2010
MAY 2012
FEB. 2013
MAR. 2013
SEPT. 2013
NOV. 2013
JAN. 2014
MAY 2014
JAN. 2015
Expanded sell-side coverage of ALQA to a total of five research firms: Alere Financial, Craig-Hallum
Capital Group, H.C. Wainwright & Co., Laidlaw & Company, & Northland Securities
FEB. 2015
CHRONIC WOUNDS
(5.1+ MILLION)
~100+
Private &
Micro-Cap
Companies
50%
~5 Large,
Diversified
Companies
50%
Burn Wounds
Pressure Ulcers
Trauma Wounds
Surgical Wounds
(~600,000)
Arterial Ulcers
ACUTE WOUNDS
(770,000+)
Pressure ulcers
2012
Revenue
$1.2M
FDA Cleared
Fully Reimbursed
SilverSeal
Name
Title
Previous Employers
Brian Posner
Brad Barton
Lori Toner
VP of Global Marketing
Gregory Robb
VP of Operations
VP of Medical Affairs
Exec. Director of Global Clinical R&D
Senior Director of Global Clinical R&D
VP of Operations
NOV. 13
NOV. 13
APR. - JUN. 13
December 31,
2014
2013
$16,770,879
$19,629,067
$29,723,724
$4,129,824
$0
*$7,212,493
$22,511,231
10
$12,100,544
$12,847,234
$17,451,568
$3,353,464
$0
$3,498,876
$13,952,696
The Criteria
Unique differentiated
Clinically efficacious
Targeting
Exudate management
Anti-microbial technologies
Regenerative medicine
11
September, 2013
Long-term, exclusive
agreement to
distribute sorbionbranded products in
the Americas
Sorbion Sachet S
sorbion Sana
LICENSING
AGREEMENTS
TARGETED
ACQUISITIONS
November, 2013
Licensing, marketing,
development and
supply agreement
with CCT, the
placental tissue &
stem cell R&D division
of Celgene
BIOVANCE
Dermal Repair
Scaffold
May, 2014
February, 2015*
Acquiring new
reimbursed
technology platform,
and sales and
reimbursement
resources
TheraBond 3D
12
MIST Therapy
UltraMIST
Use low frequency ultrasound waves to stimulate the cells below the
wound bed surface, a region that was previously inaccessible to wound
care practitioners
Reimbursed by CMS
UltraMIST System
Commercial traction
UltraMIST Applicator
13
14
FDA Clearance
Medicare Reimbursement
Hydress
n/a
SilverSeal
510(k)
sorbion Products
n/a
TheraBond 3D
510(k)
BIOVANCE
510(k)
MIST TherapySystem
*commercially available under Section 361 of the Public Health Service Act, which allows minimally manipulated human cells, tissues, and cellular
and tissue-based products (HCT/Ps) to be marketed in the United States (U.S.) without pre-market FDA approval (also called a 361 product)
15
16
$20,000,000
$15,000,000
Mid-Point
of 2015
Guidance*
$10,000,000
$5,000,000
$0
2012
Contract Manufacturing
2013
2014
*Proprietary products revenue includes contributions from the Choice Therapeutics acquisition of $323,000, $577,000 and $596,000 in
Q214, Q314 and Q414, respectively. FY15 includes mid-point of Celleration 2H15 guidance ($4.75M) and assumes a June 30th
closing date.
17
2015
Summary of Progress
New Chief Executive Officer, Chief Financial Officer, Chief Operating Officer,
Chief Medical Officer & Chief Marketing Officer
New Board members: Perry Karsen, Andrew Africk and Gary Restani
Launched BIOVANCE
Acquired Choice Therapeutics TheraBond 3D
Celgene Licensing Agreement BIOVANCE & Dermal Repair Scaffold
o Expanded to Orthopedic and Podiatric Applications
sorbion Distribution Agreement sachet S & sana
Sales Distribution
and Infrastructure
Revenue
Performance
Management &
Board Leadership
Financing
Product Portfolio
18
19
Nasdaq: ALQA
Alliqua BioMedical, Inc.
info@alliqua.com
2150 Cabot Blvd West
Langhorne, PA 19047
(215) 702-8550